O
Overview
OriGene Technologies supplies gene-based research tools and reagents to academic, pharmaceutical, and biotech researchers. Its product lines include cDNA clones, antibodies, proteins, RNAi, and lentiviral particles, sold directly to research institutions worldwide. The company produces and distributes these reagents from a large, scalable manufacturing network to ensure timely delivery and a broad catalog. Its goal is to support gene-based science by providing reliable, readily available reagents and educational resources that speed discovery, differentiating itself with a very large inventory, distributed manufacturing, and global reach.
Work here?Claim your company
Simplify's take
What believers are saying
- OriGene launched EV Isolation Reagent and CD9 Exosome ELISA on March 23, 2026.
- The August 31, 2026 review said first four flagged images matched original experimental results.
- Blog and podcast activity through November 2026 keeps the company visible to researchers.
What critics are saying
- On August 31, 2026, OriGene disclosed an investigation into Western blot image integrity.
- If validation trust breaks, researchers switch to Abcam, Thermo Fisher, and Bio-Techne quickly.
- An unresolved data-integrity scandal can crater antibody sales and damage the entire brand.
What makes OriGene Technologies unique
- OriGene sells validated gene tools across cDNA, antibodies, proteins, RNAi, and lentiviral products.
- Its large catalog includes over 100,000 primary antibodies and broad knockout-validation workflows.
- ProteanFect partnership on November 10, 2025 expands delivery options for difficult cell types.
Help us improve and share your feedback! Did you find this helpful?
Funding
Notable Investors:
Late VC funding comparison data is currently unavailable. We're working to provide this information soon!
Late VC Funding Comparison